# APIs Sector

Canonical URL: https://biopharmsignal.com/sector/apis

APIs refers to active pharmaceutical ingredients, the core chemical or biologic substances used to make medicines. Companies in this category are typically exposed to manufacturing scale, supply reliability, and the economics of pharmaceutical production rather than a single branded asset story.

Companies currently grouped under APIs: 5

## Recent Sector News

- 2026-06-25 20:01 EST — TSHA — [Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-4055adda) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — TSHA — [Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — TSHA — [Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — TSHA — [Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-completion-of-dosing-in-reveal-pivotal-trial-and-reports-longer-term-clinical-data-from-part-a-of-reveal-phase-1-2-trials-evaluating-tsha-102-for-rett-syndrome) — Source: Taysha Gene Therapies
- 2026-06-25 13:46 EST — SNDX — [Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026](https://biopharmsignal.com/news/SNDX/syndax-showcases-revuforjr-revumenib-clinical-activity-in-multiple-acute-leukemia-subtypes-and-settings-at-eha-2026) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — SNDX — [Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology](https://biopharmsignal.com/news/SNDX/syndax-announces-publication-of-save-data-on-revuforjr-revumenib-in-combination-with-decitabine-cedazuridine-and-venetoclax-in-relapsed-refractory-npm1m-kmt2ar-and-nup98r-aml-in-the-journal-of-clinical-oncology) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — RPID — [Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Rapid Micro Biosystems
- 2026-06-25 13:46 EST — SNDX — [Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes](https://biopharmsignal.com/news/SNDX/syndax-announces-private-placement-of-250-0-million-of-convertible-senior-notes) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — IOVA — [Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia](https://biopharmsignal.com/news/IOVA/iovance-s-amtagvir-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-25 13:46 EST — SNDX — [Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data](https://biopharmsignal.com/news/SNDX/syndax-highlights-revuforjr-revumenib-data-presented-at-asco-2026-including-an-oral-presentation-of-post-transplant-data) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — IOVA — [Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-announces-clearance-of-investigational-new-drug-ind-application-for-il-12-tethered-til-therapy-iov-5001) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-25 13:46 EST — SNDX — [Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026](https://biopharmsignal.com/news/SNDX/syndax-to-host-randd-day-highlighting-its-late-stage-programs-and-early-stage-assets-on-july-14-2026) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — SNDX — [Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data](https://biopharmsignal.com/news/SNDX/syndax-announces-four-revuforjr-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — IOVA — [Iovance Biotherapeutics to Present at Upcoming Conference](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-conference) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-25 13:46 EST — SNDX — [Syndax Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/SNDX/syndax-announces-participation-in-upcoming-investor-conferences) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — RPID — [Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-announces-pricing-of-up-to-approximately-32-million-underwritten-offering) — Source: Rapid Micro Biosystems
- 2026-06-25 13:46 EST — RPID — [Rapid Micro Biosystems Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-reports-first-quarter-2026-financial-results) — Source: Rapid Micro Biosystems
- 2026-06-25 13:46 EST — SNDX — [Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition](https://biopharmsignal.com/news/SNDX/syndax-highlights-12-revuforjr-revumenib-abstracts-accepted-for-eha-2026-advancing-leadership-in-menin-inhibition) — Source: Syndax Pharmaceuticals
- 2026-06-25 13:46 EST — IOVA — [Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates](https://biopharmsignal.com/news/IOVA/iovance-biotherapeutics-highlights-positive-first-quarter-2026-results-business-achievements-and-corporate-updates) — Source: Iovance Biotherapeutics, Inc.
- 2026-06-25 13:46 EST — RPID — [Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-announce-first-quarter-2026-financial-results-on-may-13-2026) — Source: Rapid Micro Biosystems

## Companies

- [ITCI](https://biopharmsignal.com/company/ITCI) — Intra-Cellular Therapies
- [IOVA](https://biopharmsignal.com/company/IOVA) — Iovance Biotherapeutics, Inc.
- [RPID](https://biopharmsignal.com/company/RPID) — Rapid Micro Biosystems
- [SNDX](https://biopharmsignal.com/company/SNDX) — Syndax Pharmaceuticals
- [TSHA](https://biopharmsignal.com/company/TSHA) — Taysha Gene Therapies